Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

June 16, 2017

Study Completion Date

June 16, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

GSK3008356

This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.

DRUG

Placebo

This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.

Trial Locations (1)

3004

GSK Investigational Site, Melbourne

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Nucleus Network Ltd

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT02742766 - Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects | Biotech Hunter | Biotech Hunter